Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Drugs Fund

- PMLiVE

Merck spins off low-growth drugs in a ‘purposeful shift’ of focus

Fourth quarter results overshadowed by spin off announcement

- PMLiVE

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

Cost-effectiveness watchdog issues a round of draft and final guidance

- PMLiVE

Keytruda claims first place in bladder cancer race

Stays ahead of rivals in the PD-1/PD-L1 inhibitor class

- PMLiVE

Keytruda doesn’t extend survival in small cell lung cancer

Unlikely to extend use into the first-line setting

- PMLiVE

Merck strengthens KRAS stake with Taiho and Astex partnership

Partner companies could gain $2.5bn in milestone payments

- PMLiVE

FDA panel clears Keytruda for hard-to-treat bladder cancer

New treatment option for high-risk patients

- PMLiVE

Lynparza cleared for first-line ovarian cancer use in China

Continues to cement lead in PARP inhibitor category

- PMLiVE

Merck’s Keytruda significantly extends life in some prostate cancer patients

Pivotal study identifies group of 'super responders'

- PMLiVE

Pfizer’s Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Around 3,200 women in England could be eligible for treatment

- PMLiVE

Merck’s Keytruda picks up third approval for NSCLC in China

New indication as a first-line treatment in combination with chemotherapy

- PMLiVE

MSD’s Keytruda scores another EU okay, in head and neck cancer

First anti-PD-1 drug to improve overall survival in first-line setting

- PMLiVE

MSD hangs ‘for sale’ sign on French facility, shedding 207 staff

Job losses will be across manufacturing and R&D divisions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links